Skip to main content

ANI Pharmaceuticals, Inc. (ANIP)

NASDAQ: ANIP · Delayed Price · USD
28.90
+0.01 (0.04%)
After-hours:Sep 17, 2021 7:53 PM EDT
28.89
0.91 (3.25%)
At close: Sep 17, 4:00 PM
Market Cap368.71M
Revenue (ttm)213.38M
Net Income (ttm)-17.22M
Shares Out12.09M
EPS (ttm)-1.43
PE Ration/a
Forward PE9.10
Dividendn/a
Ex-Dividend Daten/a
Volume298,798
Open28.16
Previous Close27.98
Day's Range27.77 - 29.35
52-Week Range23.55 - 40.00
Beta1.26
AnalystsBuy
Price Target45.00 (+55.8%)
Est. Earnings DateNov 4, 2021

About ANIP

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, ...

IndustryPharmaceuticals
Founded2001
CEOPatrick Walsh
Employees369
Stock ExchangeNASDAQ
Ticker SymbolANIP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ANIP stock is "Buy." The 12-month stock price forecast is 45.00, which is an increase of 55.76% from the latest price.

Price Target
$45.00
(55.76% upside)
Analyst Consensus: Buy

News

ANI Pharmaceuticals Announces Launch of Nebivolol Tablets

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. ANI's Nebivolol Table...

3 days ago - Business Wire

ANI Pharma's Purified Cortrophin Gel Application Under FDA Review

The FDA has accepted ANI Pharmaceuticals Inc's (NASDAQ: ANIP) supplemental marketing application for Purified Cortrophin Gel. The application seeks approval for multiple indications, including multiple ...

2 weeks ago - Benzinga

ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multip...

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq:ANIP) today announced that the Company's supplemental New Drug Application (“sNDA”) for Purified Cortrophin® ...

2 weeks ago - Business Wire

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates

ANI (ANIP) delivered earnings and revenue surprises of 3.08% and 1.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

ANI Pharmaceuticals Reports Second Quarter 2021 Results

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, ...

1 month ago - Business Wire

Analysts Estimate ANI Pharmaceuticals (ANIP) to Report a Decline in Earnings: What to Look Out for

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2021 financial results on Friday, Aug...

1 month ago - Business Wire

ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company has re-filed its supplemental new drug application (“sNDA”) for Cortr...

2 months ago - Business Wire

ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Offic...

3 months ago - Business Wire

ANI Pharmaceuticals Announces Details of 2021 Virtual Annual Meeting of Stockholders

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced log-in details for its 2021 Virtual Annual Meeting of Stockholders to be held on June ...

3 months ago - Business Wire

ANI Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Offic...

3 months ago - Business Wire

New Strong Sell Stocks for May 24th

ANIP, BHVN, FVRR, KBAL, and PLNT have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2021

Other symbols:BHVNFVRRKBALPLNT
3 months ago - Zacks Investment Research

ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Top Estimates

ANI (ANIP) delivered earnings and revenue surprises of 42.47% and 13.59%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

ANI Pharmaceuticals Reports First Quarter 2021 Results

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three months ended March 31, 2021. F...

4 months ago - Business Wire

Earnings Preview: ANI Pharmaceuticals (ANIP) Q1 Earnings Expected to Decline

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

ANI Pharmaceuticals to Discuss First Quarter 2021 Financial Results on May 7, 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2021 financial results on Friday, May ...

4 months ago - Business Wire

ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI”) (NASDAQ:ANIP) today announced that it has acquired the new drug applications (“NDAs”) for OXISTAT® Lotion, VEREGEN® Ointment, and Pand...

5 months ago - Business Wire

ANI Pharmaceuticals (ANIP) Enters Overbought Territory

ANI Pharmaceuticals (ANIP) has moved higher as of late, but there could definitely be trouble on the horizon for this company

5 months ago - Zacks Investment Research

ANI Pharmaceuticals (ANIP) Q4 Earnings Miss Estimates

ANI (ANIP) delivered earnings and revenue surprises of -20.00% and 3.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and 12 months ended December 3...

6 months ago - Business Wire

ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held...

6 months ago - Business Wire

ANI Pharmaceuticals's Earnings: A Preview

ANI Pharmaceuticals (NASDAQ:ANIP) announces its next round of earnings this Tuesday, March 09. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.

6 months ago - Benzinga

Earnings Preview: ANI Pharmaceuticals (ANIP) Q4 Earnings Expected to Decline

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced that ANI's Board of Directors granted non-qualified inducement stock options to purcha...

7 months ago - Business Wire

ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the addition of three key pharmaceutical executives: Christopher K. Mutz as Chief Comm...

7 months ago - Business Wire